Any first-mover advantage won’t last long, as some vaccine candidates may be easier to transport and administer than others.
Pfizer Has A Head Start, But The Covid-19 Vaccine Market Is Still Up For Grabs
Any first-mover advantage won’t last long, as some vaccine candidates may be easier to transport and administer than others.